During the past decade, Moscow City Clinical Hospital #1 n.a. N.I.Pirogov conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 15 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 12 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" #1 sponsor was "Actelion" with 6 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Celgene" with 3 trials sponsored, "Efferon JSC" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "Bausch Health Americas, Inc." with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator, "Kuban State Medical University" with 1 trials as a collaborator and "Ligand Research, LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" are "Multiple Sclerosis" (3 trials), "Pulmonary Arterial Hypertension" (3 trials), "Rheumatoid Arthritis" (3 trials), "Anemia" (2 trials) and "Chronic Thromboembolic Pulmonary Hypertension" (2 trials). Many other conditions were trialed in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" in a lesser frequency.

Most popular intervention types in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" are "Drug" (30 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Baricitinib" (3 trials), "GDC-0853" (2 trials), "Interferon beta-1a" (2 trials) and "Macitentan" (2 trials). Other intervention names were less common.

The vast majority of trials in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov" are 34 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Moscow City Clinical Hospital #1 n.a. N.I.Pirogov". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".